September 16, 2024 10:57 AM EDT
News Briefing

Nu­va­len­t's $350M of­fer­ing; FDA lifts par­tial hold on Zen­tal­is drug

ENDPOINTS

Plus, news about As­cendis Phar­ma, Ko­r­ro Bio, No­vo Nordisk and Medexus:

Nu­va­lent of­fers $350M in shares: The on­col­o­gy biotech is look­ing to

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Trump picks RFK Jr. for HHS; Ab­b­Vie's psych im­plo­sion; Mer­ck tries staving off Sum­mit; and more

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times